Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy

Chronic obstructive pulmonary disease (COPD) increases the risk of severe respiratory syncytial virus (RSV)-related disease. This analysis evaluated the potential public health impact and cost-effectiveness of RSV vaccination with a single dose of adjuvanted RSVPreF3 vaccine over five years in people aged 60–74 years with COPD in Italy. A static multi-cohort Markov model estimated RSV-related events, costs, and quality-adjusted life-years (QALY) over five years in people aged 60–74 years with COPD in Italy vaccinated with one dose of adjuvanted RSVPreF3, versus no vaccination. Vaccine efficacy and waning data were based on AReSVi-006 Phase III clinical trial results. Other input data came from published literature and official databases. Sensitivity analyses were conducted. A single dose of adjuvanted RSVPreF3 vaccine (75% coverage) was projected to reduce RSV-related acute respiratory infections by 29% and RSV-related hospitalizations and deaths by 38% among patients with COPD aged 60–74 years in Italy. The incremental cost-effectiveness ratio (health system perspective) was €1,306/QALY. These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60–74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.